Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Secukinumab in poorly controlled asthma
NCT01478360Phase 2Terminated
- Sponsor
- Novartis
- Start
- Mar 2012
- Primary completion
- Nov 2014
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 2 trial of secukinumab in asthma, sponsored by Novartis. Started Mar 2012; status: terminated.
02
Drugs
secukinumab
03
Conditions
asthma
Beyond the preview
Go deeper on NCT01478360.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01478360.